Autres langues Compass Therapeutics, Inc.

Actions

CMPX

US20454B1044

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 20:16:54 12/08/2026			Varia. 5j.	Varia. 1 janv.
2,175 ^USD	-1,14%		+15,08%	-59,50%

06/08	Compass Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
09/06	Transcript : Compass Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 08:00 AM

Autres langues

06/08	Compass Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
17/07	Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
30/06	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell Small Cap Comp Growth Benchmark
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell Microcap Growth Benchmark Index
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2500 Growth Benchmark
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2000 Growth Benchmark
28/05	Compass Therapeutics to Participate in Upcoming June Investor Events
21/05	Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
12/05	Compass Therapeutics to Participate in Upcoming May Investor Events
05/05	Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
05/05	Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
27/04	Compass Therapeutics : 2026 Proxy
27/04	Compass Therapeutics Tovecimig Study Falls Short on Overall Survival Endpoint in Biliary Tract Cancer; Shares Fall Pre-Bell
27/04	Compass Therapeutics Inc. tovecimig plus paclitaxel improves median PFS to 4.7 months versus 2.6 months
27/04	Top Premarket Decliners
27/04	Compass Therapeutics : Corporate Presentation
27/04	Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
27/04	Compass Therapeutics Announces Statistically Significant Benefit of Tovecimig in Companion-002 Study
27/04	Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
24/04	Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
05/03	Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025